In this article, we will discuss the 8 Best Australian Stocks to Buy in 2026.
The Australian stock market has been extremely volatile in line with other global equity indexes. The country’s main stock index, the Australia Stock Index, is flat for the year after an 8% sell-off in March on concerns that the Middle East Conflict will trigger slow economic growth and delay a US interest rate cut.
Australia started the year with an inflation problem, a situation made worse by the oil shock amid the US-Iran war. According to Morningstar Equity Market Strategist Lochlan Halloway, Australian equities are attractive after a significant pullback year to date.
For starters, the real estate and energy sectors are compelling despite energy rallying 35% year to date. Similarly, technology stocks have had a challenging start to the year, following an AI-led pullback amid high valuations.
Expanding further on the technology sector, analysts Roy van Keulen and Shaun Ler believe it is undervalued and close to levels not seen since 2022.
“We see a resilient outlook for platforms embedded in complex, regulated workflows such as WiseTech and SiteMinder,” van Keulen and Ler said.
On the other hand, the real estate sector could present tremendous opportunities in the period of rising interest rates. The Reserve Bank of Australia is expected to raise the rate in May to 4.35% in the race to address the inflation problem that threatens to get out of hand amid tight energy prices. Likewise, higher energy prices present both risks and opportunities for utilities, with Morningstar analyst Adrian Atkins noting that Australian utilities are generally slightly undervalued.
While the ASX 200 is navigating high inflation (4.8% YoY expected) and volatility, it is expected to rebound towards the 9200-level highs after falling to 8262 in March. With that in mind, let’s take a look at the Best Australian Stocks to buy in 2026.
Our Methodology
To determine our 9 best Australian stocks to buy in 2026, we used the Finviz stock screener and scanned financial media reports to identify companies listed on the Australian Securities Exchange (ASX) as well as US exchanges. We ended up with dozens of stocks and applied additional filters to pick out the best. We looked for stocks with at least 5% upside potential (as of April 23) and that are favored by hedge funds. The hedge fund data was picked from Insider Monkey’s database as of Q4 2025. Finally, we ranked the stocks based on their price upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best Australian Stocks to Buy in 2026
8. Amcor PLC (NYSE:AMCR)
Stock Upside Potential: 25.16%
Number of Hedge Fund Holders: 30
Amcor PLC (NYSE:AMCR) is among the best Australian stocks to buy in 2026. On April 21, Amcor PLC (NYSE:AMCR) announced that it has collaborated with Metsa Group and G. Mondini to accelerate a fiber-based packaging solution for the food industry. Metsa is a Finnish forest industry group, while G. Mondini is a food packaging provider.
The fiber packaging is in a tray-and-film combination format. Amcor said that this fiber-based packaging solution is engineered for protein and chilled ready‑meal applications. The company further said the fiber packaging is designed to protect perishable foods and to prolong shelf life.
For brands, Amcor said the fiber solution offers a distinctive format and supports their environmental commitments, as this solution can help cut plastic use. Also, Amcor pointed out that the fiber packaging solution responds to growing consumer confidence in sustainable materials.
Amcor noted that the fiber packaging solution partnership benefits from Metsa’s expertise in processing wood and G. Mondini’s packaging machinery expertise. Amcor itself brings barrier film technology to the collaboration.
As Amcor advances innovation in sustainable materials with fiber packaging solutions, Deutsche Bank has identified it as a solid investment. On April 7, Deutsche Bank named Amcor among its top packaging stocks in 2026. The bank highlighted Amcor’s exposure to defensive segments like food and healthcare, global footprint, strong pricing power, and cost discipline. In this light, Deutsche Bank believes Amcor is less vulnerable to macroeconomic pressures.
Amcor PLC (NYSE:AMCR) is an Australian-founded global packaging solutions company. It develops and produces packaging products for diverse industries, including food and beverage, personal and home-care, and healthcare. The company operates in more than 40 countries.
7. Life360, Inc. (NASDAQ:LIF)
Stock Upside Potential: 47.12%
Number of Hedge Fund Holders: 20
Life360 Inc (NASDAQ:LIF) is among the best Australian stocks to buy in 2026. On April 22, BofA Securities initiated coverage of Life360 Inc (NASDAQ:LIF) stock with a Buy rating and a price target of $60. The firm sees continued growth and profitability improvement at Life360.
BofA Securities expects Life360 to continue adding more users to its family safety app. It estimates that the company’s users will increase at a compound annual growth rate of 18% in the 2025 – 2027 period. The firm sees Life360’s user-base expansion benefiting from the company’s strong position in the family safety app category and a large global opportunity.
On the financial side, BofA Securities expects Life360’s revenue to grow at a compound annual rate of 31% over the 2025-2027 period. It expects EBITDA growth of 47% over the same timeframe. Moreover, the firm expects Life360’s financials to exceed consensus estimates by 2% to 5%.
BofA Securities highlighted a number of growth tailwinds for Life360. Expanding product portfolio is one of them, with the firm citing the company’s elderly tracker and pet tracker products.
The firm also mentioned the planned Uber integration as a catalyst. In an expansion of their existing partnership, Life360 and Uber announced on February 17 a deeper integration of their services. They said this would allow families to coordinate transportation and tracking more easily.
In 2025, Life360’s monthly active users increased 20% YoY to 95.8 million, and revenue rose 32% YoY to $489.5 million.
Life360 Inc (NASDAQ:LIF) provides a family safety mobile app used by millions around the world. The app helps with functions like real-time tracking and location history. It also offers safety features like SOS alerts and crash detection. Families use it to stay connected and ensure their safety.
6. Tamboran Resources Corp (NYSE:TBN)
Stock Upside Potential: 60.70%
Number of Hedge Fund Holders: 14
Tamboran Resources Corp (NYSE:TBN) is among the best Australian stocks to buy in 2026. Tamboran Resources Corp (NYSE:TBN) has recently completed several fundraising programs.
On April 15, the company announced that it had completed the final part of a series of direct equity offerings to a certain group of institutional investors. That final transaction involved the sale of an additional 96,698 shares of common stock. Tamboran Resources previously issued 916,412 shares to this same group of investors in a transaction that was announced as closed on April 14.
Separately, on April 14, the company said that it had completed an accelerated equity offering to a group of existing institutional shareholders outside the US. In this transaction, Tamboran Resources issued depository interests representing 741,542 shares of its common stock. The transaction generated A$37.1 million in total proceeds.
Also on April 14, Tamboran Resources announced the completion of the sale of an additional 443,491 shares of its common stock through an underwritten offering. It said that this transaction raised $14.7 million in net proceeds.
Tamboran’s underwritten offering was announced way back on April 7. At that time, the company said it would offer around 2.96 million shares at a price of $35 per share. It said that it would grant the underwriters the option to purchase an additional 443,491 shares. The company hoped to raise $103.5 million in gross proceeds through the underwritten offering before including the potential sale of additional shares.
Tamboran intended to use net proceeds from these offerings to fund its drilling operations in Australia.
Tamboran Resources Corp (NYSE:TBN) is an energy company founded in 2009. The company specializes in low-carbon natural gas production in the Beetaloo Basin in Australia. Tamboran Resources is focused on meeting domestic natural gas demand in Australia and supporting gas exports to the Asia-Pacific.
5. Telix Pharmaceuticals Limited (NASDAQ:TLX)
Stock Upside Potential: 71.85%
Number of Hedge Fund Holders: 4
Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best Australian stocks to buy in 2026. Telix Pharmaceuticals Limited (NASDAQ:TLX) is using a combination of internal programs and partnership arrangements to expand its product portfolio. On April 21, the company announced that it plans to present clinical trial data for its prostate cancer drug candidate at the American Society of Clinical Oncology Annual Meeting. This event is planned for May 29 to June 2 in Chicago.
The presentation will focus on the safety and tolerability of TLX591-Tx based on the findings from Part 1 of the ProstACT Global Phase 3 study. The Part 1 trial assessed the safety, tolerability, biodistribution, and radiation dose profile of the drug candidate in patients with castration-resistant prostate cancer. Some 36 patients were enrolled for this trial. Part 2 trial targets around 490 patients with castration-resistant prostate cancer after prior treatment.
Telix Pharmaceuticals Limited has more than a dozen clinical trials underway worldwide. These include the trial of a potential brain cancer therapy. On April 14, Telix announced that the first patient had been dosed in the Phase 3 IPAX-BrIGHT trial of its brain cancer drug candidate TLX101-Tx. The company cast this as a milestone, noting that TLX101-Tx is the first radiopharmaceutical therapy for glioblastoma to enter Phase 3 development.
Away from internal efforts, Telix Pharmaceuticals Limited is also forging strategic partnerships. On April 13, the company announced a collaboration with Regeneron Pharmaceuticals to develop and commercialize radiopharmaceutical treatments for cancer patients. The companies agreed to share costs and profits. Telix Pharmaceuticals Limited said it could earn as much as $2.1 billion in milestone payments from this arrangement.
Telix Pharmaceuticals Limited (NASDAQ:TLX), based in Melbourne, Australia, is a global biopharmaceutical company. It develops radiopharmaceuticals products for cancer diagnosis and treatment. Its prostate cancer imaging agent has won regulatory approvals in Australia, the US, and Canada. The company’s pipeline features more than 18 ongoing clinical trials globally.
4. Kazia Therapeutics Ltd (NASDAQ:KZIA)
Stock Upside Potential: 105.08%
Number of Hedge Fund Holders: 6
Kazia Therapeutics Ltd (NASDAQ:KZIA) is among the best Australian stocks to buy in 2026. Kazia Therapeutics Ltd (NASDAQ:KZIA) recently strengthened its team and expanded its platform as it works to address unmet needs in the cancer treatment space. On April 15, the company announced the appointment of Sudha Rao as its chief scientific officer.
Rao brings over 20 years of pharmaceutical research and development experience to Kazia, which says this will strengthen its scientific leadership team. Rao is the lead inventor on some 39 international patents.
At Kazia, Rao will lead research and development activities for the company’s drug pipeline. This will involve overseeing the company’s flagship paxalisib program, which is being developed as a therapy for brain cancer, breast cancer, and other oncology indications.
Kazia CEO John Friend said that Rao is a leading breast cancer researcher and translational epigenetics scientist. Notably, Rao came shortly after Kazia said on April 13 that it has licensed a drug development platform from QIMR Berghofer for around $1.39 million.
Separately on April 15, the equity research firm Laidlaw initiated coverage of Kazia Therapeutics Ltd (NASDAQ:KZIA) with a Buy rating and a price target of $25. For this bullish view, Laidlaw pointed to the potential of Kazia’s lead drug candidate paxalisib. The firm cited a Phase 1b study finding that all treated patients demonstrated efficacy. Laidlaw noted that the study is ongoing and expects more results in 2026 and 2027.
Additionally, Laidlaw noted that Kazia and the FDA will meet in Q2 2026 to discuss the next development step for paxalisib in brain cancer. According to the firm, the meeting could lead to Phase 3 study for a standard approval of paxalisib.
Kazia Therapeutics Ltd (NASDAQ:KZIA) is a biotechnology company focused on developing cancer treatments. The company’s product pipeline includes potential therapies for brain cancer, liver cancer, and renal cancer. Kazia Therapeutics aims to address cancer treatment areas underserved by existing therapies.
3. Mesoblast Ltd (NASDAQ:MESO)
Stock Upside Potential: 116.32%
Number of Hedge Fund Holders: 5
Mesoblast Ltd (NASDAQ:MESO) is among the best Australian stocks to buy in 2026. On April 14, Mesoblast Ltd (NASDAQ:MESO) announced that it has secured exclusive global rights to a patented technology platform from Mayo Clinic. This platform uses chimeric antigen receptors, and it helps improve the performance of mesenchymal lineage stromal cell (MSC) therapeutic products.
The company said the platform is designed to help mesenchymal stromal cells to better locate and act on inflamed tissue. Mesoblast plans to use the technology to sharpen the ability of its therapies to more precisely and effectively target areas of disease, increase immune response, and support tissue regeneration.
With this platform, Mesoblast sees an opportunity to generate therapies for diseases such as ulcerative colitis and Crohn’s disease. Moreover, the company sees potential for therapies for other immune disorders with the CAR technology platform in its grasp.
The CAR technology platform was developed by scientists at Mayo Clinic, and the license was held by a startup formed by Mayo Clinic. Mesoblast acquired that startup to secure the exclusive rights to the platform. Mayo Clinic will continue to support Mesoblast in advancing the technology and products tied to the platform.
Mesoblast paid for the license acquisition with its shares, though the financial details of the transaction were not disclosed.
Mesoblast Ltd (NASDAQ:MESO) is an Australian biotech company founded in 2004 and based in Melbourne. The company develops treatments for a variety of health problems, including inflammatory ailments, cardiovascular disease, and back pain.
2. Ioneer Ltd ADR (NASDAQ:IONR)
Stock Upside Potential: 182.14%
Number of Hedge Fund Holders: 3
Ioneer Ltd ADR (NASDAQ:IONR) is among the best Australian stocks to buy in 2026. Ioneer Ltd ADR (NASDAQ:IONR) is fighting to save its proposed lithium and boron mining project in Nevada. On April 8, the company said that it is confident that the appeals court will affirm a judge’s ruling regarding its Nevada project permit. The company said this in response to an appeal filed earlier that day by environmentalists challenging the approval of its lithium mining project in Nevada.
Ioneer secured the final federal permit for the Rhyolite Ridge lLithium-Boron Project in 2024. But the project approval was swiftly challenged in court. On March 31, a judge at a US district court in Nevada upheld the approval, and Ioneer said the project would strengthen America’s supply chain of critical materials and bolster national security. But environmentalists appealed the judge’s decision. Ioneer holds that the permit was granted properly and that the appeals court will rule in its favor.
Rhyolite Ridge mine is intended to produce lithium and boron, materials used in electric cars and renewable energy. In 2022, Ioneer signed offtake agreements with Ford Motor Company and a joint venture of Toyota and Panasonic. Last year, Ioneer secured a $996 million loan for the project with the U.S. Department of Energy.
Sydney-based Ioneer Ltd ADR (NASDAQ:IONR) is a mining company focused on supplying lithium and other materials used in electric car and renewable energy industries. Ioneer Ltd is developing a lithium-boron project in Nevada, US that will help strengthen the domestic supply chain of critical materials.
1. Radiopharm Theranostics ADR (NASDAQ:RADX)
Stock Upside Potential: 383.35%
Number of Hedge Fund Holders: 3
Radiopharm Theranostics ADR (NASDAQ:RADX) is among the best Australian stocks to buy in 2026. Radiopharm Theranostics ADR (NASDAQ:RADX) continues to advance its clinical programs with solid results. On April 20, the company presented initial findings from an early-stage trial of its cancer drug candidate at the American Association for Cancer Research Annual Meeting.
The drug candidate, 177Lu-RAD202, is being developed as a treatment for various cancers, including breast cancer. In the Phase 1 HEAT clinical trial, 177Lu-RAD202 was evaluated in patients with advanced HER2-positive breast and urothelial cancers. These patients had been through multiple metastatic therapies before. In this trial, they received the lowest dose of 30 mCi.
In this study, 177Lu-RAD202 showed encouraging tumor uptake. It also demonstrated a favorable safety profile. With these findings, Radiopharm has been approved to advance the trial to the next dose level of 130 mCi. This dose escalation approval covers cohort 1 and cohort 2.
The company is conducting the Phase 1 HEAT study at clinical centers across Australia. It aims to complete the Phase 1 dose escalation by the end of this year.
At this point, Radiopharm has a busy clinical program, with a pipeline that includes five Phase 1 trials and one Phase 2 trial. These trials cover diverse cancer types, including lung cancer, prostate cancer, breast cancer, and brain cancer.
On April 7, Radiopharm announced a supply deal with Siemens for its brain cancer drug program. Under this deal, Siemens will manufacture and supply doses of Radiopharm’s drug candidate RAD101 for Phase 3 registrational trials in the US.
Radiopharm Theranostics ADR (NASDAQ:RADX), headquartered in Melbourne, Australia, is a biotech focused on developing products for cancer care. It specializes in developing first-in-class radiopharmaceuticals for cancer diagnosis and treatment.
READ NEXT: 12 Best Falling Stocks to Invest In Now and 10 Best 52-Week High US Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
